Generated by AI
Prothena Corp PLC is a clinical-stage biotechnology company focused on discovering and developing therapies for diseases linked to protein dysregulation. The company’s current work centers on investigational treatments for neurodegenerative disorders and rare peripheral amyloid diseases, areas where misfolded proteins play a critical role in disease progression. Its pipeline includes both wholly owned and partnered programs aimed at conditions such as Alzheimer’s disease, Parkinson’s disease, AL amyloidosis, and ATTR amyloidosis. Prothena Corp PLC also applies its proprietary scientific platform to investigate targeted biologic therapies designed to address complex disease pathways in the brain and peripheral tissues. Headquartered in Dublin, Ireland, Prothena Corp PLC plays a specialized role in the biotechnology market by advancing experimental medicines for serious disorders with limited treatment options.
Website77 Sir John Rogerson’s Quay
Dublin, D02 VK60
Ireland
The latest articles about PRTA.
DUBLIN, October 29, 2026--Prothena to Report Third Quarter 2026 Financial Results on November 5
Summary of May 27's posts. Generated by AI.
Summary of Oct 16's posts. Generated by AI.
Summary of Jul 13's posts. Generated by AI.
Summary of Oct 16's posts. Generated by AI.
Investors talking about PRTA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.